Veradigm (OTC:MDRX) said that it's ending a strategic review after it received no firm proposals in its process. The electronic medical records firm disclosed that five bidders made preliminary ...

With the introduction of seven new disease-specific registry datasets, Veradigm is enabling deep, targeted research to drive innovation and enhance real-world clinical insights Veradigm’s ...

Veradigm is ending its review of strategic alternatives for the company almost eight months after the process began. The healthcare technology company on Thursday said that while five bidders ...

Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, today announced the integration of two new datasets to expand the depth and breadth of Veradigm Network ...

CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that the Veradigm Board of Directors (the “Board ...

Shares of MDRX stock opened at $5.20 on Thursday. Veradigm has a 12 month low of $4.50 and a 12 month high of $11.80. The business’s 50 day moving average is $8.70 and its two-hundred day moving ...

CHICAGO--(BUSINESS WIRE)--Veradigm ® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today the launch of its disease-specific cardiometabolic Clinical ...